Assignee
BIODESIX INC
US·41 granted patents·12 pending applications·372 citations·filing 2006–2023
Top patents by PatentIndex Score
53 records- 0198US7736905B2Method and system for determining whether a drug will be effective on a patient with a diseaseBIODESIX INC·Filed 2006·Granted Jun 15, 2010·72 cites·18 claims
- 0296US8718996B2Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agentsBIODESIX INC·Filed 2013·Granted May 6, 2014·19 cites·10 claims
- 0395US10489550B2Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sampleBIODESIX INC·Filed 2017·Granted Nov 26, 2019·13 cites·7 claims
- 0495US7906342B2Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samplesBIODESIX INC·Filed 2009·Granted Mar 15, 2011·23 cites·3 claims
- 0595US7879620B2Method and system for determining whether a drug will be effective on a patient with a diseaseBIODESIX INC·Filed 2010·Granted Feb 1, 2011·24 cites·8 claims
- 0695US7858389B2Selection of non-small-cell lung cancer patients for treatment with monoclonal antibody drugs targeting EGFR pathwayBIODESIX INC·Filed 2009·Granted Dec 28, 2010·30 cites·4 claims
- 0793US10802027B2Compositions, methods and kits for diagnosis of lung cancerBIODESIX INC·Filed 2017·Granted Oct 13, 2020·6 cites·15 claims
- 0893US10007766B2Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methodsBIODESIX INC·Filed 2016·Granted Jun 26, 2018·9 cites·8 claims
- 0993US9779204B2Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sampleBIODESIX INC·Filed 2015·Granted Oct 3, 2017·7 cites·6 claims
- 1093US9563744B1Method of predicting development and severity of graft-versus-host diseaseBIODESIX INC·Filed 2015·Granted Feb 7, 2017·9 cites·11 claims
- 1193US9477906B2Classification generation method using combination of mini-classifiers with regularization and uses thereofBIODESIX INC·Filed 2014·Granted Oct 25, 2016·21 cites·39 claims
- 1292US10217620B2Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometryBIODESIX INC·Filed 2018·Granted Feb 26, 2019·6 cites·10 claims
- 1392US9279798B2Deep-MALDI TOF mass spectrometry of complex biological samples, e.g., serum, and uses thereofBIODESIX INC·Filed 2013·Granted Mar 8, 2016·18 cites·21 claims
- 1492US7858390B2Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathwayBIODESIX INC·Filed 2009·Granted Dec 28, 2010·26 cites·7 claims
- 1591US11894147B2Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findingsBIODESIX INC·Filed 2022·Granted Feb 6, 2024·2 cites·7 claims
- 1691US10037874B2Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometryBIODESIX INC·Filed 2015·Granted Jul 31, 2018·6 cites·9 claims
- 1790US11594403B1Predictive test for prognosis of myelodysplastic syndrome patients using mass spectrometry of blood-based sampleBIODESIX INC·Filed 2018·Granted Feb 28, 2023·4 cites·11 claims
- 1890US11476003B2Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findingsBIODESIX INC·Filed 2021·Granted Oct 18, 2022·3 cites·10 claims
- 1990US7867775B2Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathwayBIODESIX INC·Filed 2009·Granted Jan 11, 2011·21 cites·5 claims
- 2089US9606101B2Deep MALDI TOF mass spectrometry of complex biological samples, e.g., serum, and uses thereofBIODESIX INC·Filed 2015·Granted Mar 28, 2017·7 cites·6 claims
- 2189US9211314B2Treatment selection for lung cancer patients using mass spectrum of blood-based sampleBIODESIX INC·Filed 2014·Granted Dec 15, 2015·6 cites·30 claims
- 2288US10338074B2Compositions, methods and kits for diagnosis of lung cancerBIODESIX INC·Filed 2016·Granted Jul 2, 2019·3 cites·13 claims
- 2387US10713590B2Bagged filtering method for selection and deselection of features for classificationBIODESIX INC·Filed 2016·Granted Jul 14, 2020·5 cites·24 claims
- 2487US9254120B2Method for predicting breast cancer patient response to combination therapyBIODESIX INC·Filed 2013·Granted Feb 9, 2016·5 cites·8 claims
- 2586US11467167B2SRM methods in Alzheimer's disease and neurological disease assaysBIODESIX INC·Filed 2019·Granted Oct 11, 2022·1 cites·16 claims
- 2685US10950348B2Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methodsBIODESIX INC·Filed 2018·Granted Mar 16, 2021·2 cites·11 claims
- 2784US10422729B1Blood sample separation devices and methodsBIODESIX INC·Filed 2019·Granted Sep 24, 2019·4 cites·20 claims
- 2881US8024282B2Method for reliable classification of samples in clinical diagnostics using an improved method of classificationBIODESIX INC·Filed 2008·Granted Sep 20, 2011·11 cites·34 claims
- 2979US11913957B2Compositions, methods and kits for diagnosis of lung cancerBIODESIX INC·Filed 2017·Granted Feb 27, 2024·1 cites·12 claims
- 3079US11150238B2Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroupsBIODESIX INC·Filed 2018·Granted Oct 19, 2021·1 cites·8 claims
- 3177US12094587B2Apparatus and method for identification of primary immune resistance in cancer patientsBIODESIX INC·Filed 2019·Granted Sep 17, 2024·1 cites·19 claims
- 3275US11710539B2Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapyBIODESIX INC·Filed 2017·Granted Jul 25, 2023·1 cites·4 claims
- 3375US9653272B2Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapiesBIODESIX INC·Filed 2013·Granted May 16, 2017·2 cites·72 claims
- 3474US11621057B2Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapyBIODESIX INC·Filed 2017·Granted Apr 4, 2023·1 cites·11 claims
- 3574US10593529B2Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapiesBIODESIX INC·Filed 2017·Granted Mar 17, 2020·1 cites·15 claims
- 3674US2023197426A1Predictive test for prognosis of myelodysplastic syndrome patients using mass spectrometry of blood-based sampleBIODESIX INC·Filed 2023·Application pending·0 cites
- 3773US12247980B2Compositions, methods and kits for diagnosis of lung cancerBIODESIX INC·Filed 2021·Granted Mar 11, 2025·0 cites·10 claims
- 3871US10870891B2Diagnostic test system for specific, sensitive and reproducible detection of circulating nucleic acids in whole bloodBIODESIX INC·Filed 2018·Granted Dec 22, 2020·1 cites·15 claims
- 3970US12230398B2Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methodsBIODESIX INC·Filed 2020·Granted Feb 18, 2025·0 cites·7 claims
- 4069US2022026416A1Method for identification of cancer patients with durable benefit from immunotehrapy in overall poor prognosis subgroupsBIODESIX INC·Filed 2021·Application pending·0 cites
- 4166US11193935B2Compositions, methods and kits for diagnosis of lung cancerBIODESIX INC·Filed 2017·Granted Dec 7, 2021·0 cites·18 claims
- 4266US2021285950A1Compositions, methods and kits for diagnosis of lung cancerBIODESIX INC·Filed 2020·Application pending·0 cites
- 4366US2021318320A1Calibrator for immunoassaysBIODESIX INC·Filed 2020·Application pending·0 cites
- 4465US2019056402A1Organ specific diagnostic panels and methods for identification of organ specific panel proteinsBIODESIX INC·Filed 2018·Application pending·0 cites
- 4564US10534002B2Selected reaction monitoring assaysBIODESIX INC·Filed 2017·Granted Jan 14, 2020·0 cites·12 claims
- 4659US2014200825A1Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agentsBIODESIX INC·Filed 2014·Application pending·0 cites
- 4757US2014284468A1Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samplesBIODESIX INC·Filed 2014·Application pending·0 cites
- 4855US2016019342A1Treatment selection for lung cancer patients using mass spectrum of blood-based sampleBIODESIX INC·Filed 2015·Application pending·0 cites
- 4952US2025379043A1Sensitive and accurate feature values from deep maldi spectraBIODESIX INC·Filed 2023·Application pending·0 cites
- 5050US11542340B1Antibodies targeting pulmonary nodule specific biomarkers and uses thereofBIODESIX INC·Filed 2021·Granted Jan 3, 2023·0 cites·18 claims
Showing the top 50 of 53 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when BIODESIX INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →